key: cord-0748206-g1u9jods
authors: Chen, Y.; Ouyang, L.; Bao, S.; Li, Q.; Han, L.; Zhang, H.; Zhu, B.; Xu, M.; Liu, J.; Ge, Y.; Chen, S.
title: An Interpretable Machine Learning Framework for Accurate Severe vs Non-severe COVID-19 Clinical Type Classification
date: 2020-05-22
journal: nan
DOI: 10.1101/2020.05.18.20105841
sha: 690a845f253da974c9ce234f607b23b1bc5ee62c
doc_id: 748206
cord_uid: g1u9jods

Effectively and efficiently diagnosing COVID-19 patients with accurate clinical type is essential to achieve optimal outcomes of the patients as well as reducing the risk of overloading the healthcare system. Currently, severe and non-severe COVID-19 types are differentiated by only a few clinical features, which do not comprehensively characterize complicated pathological, physiological, and immunological responses to SARS-CoV-2 invasion in different types. In this study, we recruited 214 confirmed COVID-19 patients in non-severe and 148 in severe type, from Wuhan, China. The patients' comorbidity and symptoms (26 features), and blood biochemistry (26 features) upon admission were acquired as two input modalities. Exploratory analyses demonstrated that these features differed substantially between two clinical types. Machine learning random forest (RF) models using features in each modality were developed and validated to classify COVID-19 clinical types. Using comorbidity/symptom and biochemistry as input independently, RF models achieved >90% and >95% predictive accuracy, respectively. Input features' importance based on Gini impurity were further evaluated and top five features from each modality were identified (age, hypertension, cardiovascular disease, gender, diabetes; D-Dimer, hsTNI, neutrophil, IL-6, and LDH). Combining top 10 multimodal features, RF model achieved >99% predictive accuracy. These findings shed light on how the human body reacts to SARS-CoV-2 invasion as a unity and provide insights on effectively evaluating COVID-19 patient's severity and developing treatment plans accordingly. We suggest that symptoms and comorbidities can be used as an initial screening tool for triaging, while biochemistry and features combined are applied when accuracy is the priority.

comprehensive experience on the emerging COVID-19. We aim to explore and contrast the 105 distributions of comorbidities and symptoms, as well as blood biochemistry between non-severe 106 and severe COVID-19 types. We will identify key features that differed substantially between 107 the two clinical types and provide clear evidence-based interpretations for clinicians and other 108 health professionals. Next, we will investigate whether single modality or specific combination 109 of features across modalities are able to provide accurate classification models based on ML 110

techniques. This study delivers an accurate diagnostic decision support tool to differentiate non-111 severe from severe type patients based on commonly available clinical data with clear clinical 112

interpretations. Insights gained from this study, as well as developed end-to-end multimodal data 113 analysis and ML framework, will enable us to better understand the comprehensive pathology of 114 COVID-19, further distinguish COVID-19 from other infectious respiratory diseases, and apply 115 in other diseases with multimodal clinical data in the future. 116

Data Mining of COVID-19 Clinical Features between Non-severe and Severe Types 118

Prevalence of symptom features in non-severe and severe COVID-19 types were 119 calculated and compared (Fig. 1) . Patients in the two clinical types showed distinct prevalence of 120 many features. Severe COVID-19 patients were statistically much more likely to be elderly ( develop (SOR, OR=0.30, 95% CI=0.14-0.61, p<0.001). Since some of these clinical conditions 130

were self-reported symptoms, observation biases were to be expected. These discoveries were 131 further demonstrated in the forest plot of odds ratio (OR) and CI in Fig. 2 , showing the 132 differences between the two clinical types. Therefore, these relatively easily measured and 133 acquired clinical features could be utilized to clinically evaluate COVID-19 patients' severity. 134

Our findings also echoed the U.S. CDC's recently updated list of symptoms of COVID-19 (21) 135 and more recent reports on characterizations of COVID-19 patients in the U.S. (36). Our findings 136

showed that elderly male COVID-19 patients with cardiovascular, respiratory, renal diseases and 137 diabetes were at much higher risk of developing serious complications of COVID-19 such as 138 acute respiratory distress syndrome (ARDS) and even death (19, 20) . In addition, we discovered 139 that Chinese patients with renal diseases were significantly more likely to develop severe 140 COVID-19, which was not widely reported before. Clinical evidence showed that ACE-2 141 expression was associated with kidney diseases, thus making kidney disease a potential 142 complication of SARS-CoV-2 invasion (22,23). This finding would inform clinicians to monitor 143 kidney dysfunction, e.g., acute kidney injury, as a clinical sign and/or consequence of severe 144 COVID-19 complication as well. 145

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 22, 2020. . COPD. The threshold for a feature to be "positively" or "negatively" associated with severe 155 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 22, 2020. .

We first explored whether the relatively simple binary symptom features could provide 183 accurate insights on COVID-19 severity. Model performance was summarized in Table 1 upper  184 section. Based on 100 independent runs, the RF model reached an average of >99% and 92% 185 accuracy for training and testing sets, respectively (Table 1) . AUC was 90.2% (82.9%-97.6%) 186 based on the receiver operating characteristic (ROC) curve ( Fig. 4 left panel) . The model 187 performed better in detecting true positives (i.e., severe type) than true negatives (i.e., non-severe 188 type). In other words, symptom features alone in RF models almost never falsely predicted 189 severe case as non-severe case, but with a higher chance to predict non-severe case to severe 190 case. In clinical practice, this would be a lesser concern, as false positive (failed to detect mild 191 type) would be more tolerable than false negative (failed to detect severe type). 192

Our RF model also provided the major influential features to differentiate COVID- 19 193 types based on contribution to Gini impurity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 22, 2020. the-art ML models could achieve. 228

Top differentiating features in biochemistry modality were D-dimer (DD), high 229 sensitivity troponin I (hsTNI), neutrophil (NE), interleukin-6 (IL-6), lactate dehydrogenase 230 (LDH), and high sensitivity c-reative protein (hsCRP). The clinical interpretation of their 231 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2020. . important role was that severe COVID-19 patients had more intensive immune response and  232 hyperinflammation, such as cytokine storm syndrome with substantially increased IL-6 (25). 233

Research also showed that SARS-CoV-2 was able to infect many organs other than lungs and 234 induce dysfunction of these organs, including heart (26,27). Increasing hsTNI was a sign of heart 235 tissue damage from SARS-CoV-2 infection (28). In addition, severe COVID-19 patients might 236 have formed microthrombosis which induced higher D-dimer (18, 20,29-31). Abnormal level of 237 neutrophils could be responsible for cytokine storm and ARDS in severe COVID-19 patients 238

(13,32). hsCRP, a biomarker of acute inflammation, cardiovascular disease, and ischemic events, 239

was also confirmed as the major contributing factor of COVID-19 mortality (18 as well (Fig. 4 right panel) . Therefore, we suggested a two-step evaluation process of COVID-19 253 patient's severity in clinical practice. Biochemistry and multimodal features such as a 254

combination of symptom and biochemistry would serve as a more robust second-round 255 confirmation after the first round of initial screening based on binary comorbidity and symptom 256

features. 257

These findings reinforced our argument that SARS-CoV-2 attacked multiple organs and 258 systems, and the human body reacted in a unity against its invasion. Different clinical features 259 (e.g., comorbidity, symptom, and biochemistry) complemented each other to provide a more 260 comprehensive characterization of human body as a united entity, not just respiratory system, 261

reacted to SARS-CoV-2 invasion (35). In addition, the decent model performance promised the 262 feasibility of multimodal clinical data mining in detecting and differentiating non-severe from 263

severe COVID-19 patients. Our work would help effectively optimize healthcare operation 264 during the pandemic and avoid overloading the healthcare system (7). 265

This study provides a breakthrough in combining the power of multiple clinical features 267 from different modalities to differentiate COVID-19 clinical types via machine learning 268

techniques. Practically, it enables delivering a more effective and efficient COVID-19 clinical 269 type diagnostic decision support system. It helps develop optimal treatment plans for the 270 individual patient, for example, sending to a mobile cabin hospital or admitting to a hospital with 271 ICU (8). In addition, it will enable triaging and more effectively optimize the healthcare system 272 resources and staffing. Doing so will substantially reduce the risk of overloading the healthcare 273 system by admitting all COVID-19 patients into the hospital, decrease potential healthcare-274 associated infections, and improve clinical outcome for the patients, especially during this 275 COVID-19 pandemic (7). 276 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) almost as capable of transmitting the virus as symptomatic patients (4-6). We suggest that the 302 term "asymptomatic" may be due to lack of a comprehensive evaluation and understanding of 303 this novel pathogen and hosts' pathophysiology, and not truly "asymptomatic". By more 304 extensive data mining we show that non-severe COVID-19 patients have many symptoms 305 differently distributed than severe patients. Our study provides an alternative route to detect non-306

severe COVID-19 patients and complement current biomedical imaging procedures. 307

The next step of this study is to further include biomedical imaging modality. A technical 308 barrier is that CT scan is a high-dimensional feature set while symptom and biochemistry have 309 relatively low dimensionality. Therefore, CT scan, at its original form of imaging, cannot be 310 effectively combined with other modalities. We will evaluate the feasibility of using convolution 311 neural network (CNN, another time of ML technique) first to reduce feature space in CT scan 312

and extracting a fully connected layer in CNN as a representation of CT scan feature. A fully 313 connected layer is a 1-dimensional vector and has the same dimensionality with the other two 314 modalities. Therefore, in theory we would be able to further combine CT scans with other 315 clinical features and investigate the association between these features with regard to COVID-19. 316

COVID-19 is a complex disease where the pathogen not only attacks the respiratory 317 system but other organs and systems that have ACE-2 receptors as well (35,36). Our findings 318 reveal the complicated pathological, physiological, and immunological responses to SARS-CoV-319 2 invasion and shed light in understanding the complex interactions between the virus and human 320 body. Though the multimodal data mining and ML framework is developed with severe/non-321

severe COVID-19 data, we suggest that the end-to-end framework is applicable to many disease 322 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105841 doi: medRxiv preprint systems where multimodal inputs are common, including demographic information, comorbidity, 323 biochemistry, imaging, and -omics data. Having a more holistic viewpoint and approach will 324 enable us to understand and respond to these emerging diseases, especially the unprecedented 325 COVID-19, more readily in the field. We will further explore this analytical framework, and 326 transfer insights for future clinical studies such as differentiating healthy, non-COVID viral 327 pneumonia, non-severe, and severe COVID-19 patients. 328

In this study, we recruited participants from a single hospital in Wuhan, the first epicenter 329 of COVID-19. There will inevitably be selection bias, as currently the ethnicity group is limited 330

to Chinese participants. Therefore, we want to inform our colleagues across the world and see 331

whether different demographic backgrounds influence feature distributions between non-severe 332 and severe types in the patients. Our findings have already been independently identified in 333 COVID-19 patients across ethnicity groups (21, 28). Another pitfall we should be aware of is 334 that comorbidities may be the consequence of SARS-CoV-2 invasion, or risk factors that 335

increase the risk of infection. Although the participants' comorbidity, symptom, and 336 biochemistry were evaluated upon admission to hospital, they could have been exposed to the 337 pathogen long before hospitalization, given the long "asymptomatic" type of COVID-19. For 338 example, it is unclear whether kidney damage in a patient is a risk factor to induce severe type 339 COVID-19, or SARS-CoV-2 attacks the kidney and causes kidney damage (35 (9-11). Patients in severe type should present any one of the following features: 1) respiratory 360 rate > 30 breaths per minute; 2) oxygen saturation < 93% at rest; or 3) arterial oxygen partial 361 pressure (PaO 2 )/fraction of inspired oxygen (FiO 2 ) < 300mmHg (40kPa). Each COVID-19 362 patient was confirmed by two independent qRT-PCR tests before admitted to this study. All 363 patients signed informed consent forms before participation. Symptoms were evaluated and 364 blood samples were drawn upon admission. No pediatric patients younger than 18 years old were 365 admitted in this study. This study was evaluated and approved by the IRB committee of Union 366

Hospital, Wuhan, China (approval number: 2020-IEC-J-345). 367 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2020. .

first modality was a total of 26 pre-existing comorbidities and clinical symptoms, colloquially 369 referred to as symptom features hereinafter. These features included gender, age (dichotomized 370 as elder and young using 50yr as a cut-off point), hypertension, coughing, different types of 371 fever, etc. A detailed description of these 26 features was provided in supplementary table S1. 372

All symptom features were coded as 0-1 binary variables. 373

In addition, we also collected patients' blood samples and performed blood chemistry 374 testing. After initial screening, we excluded some features with too many missing data such as 375 calcitonin. Oxygen saturation and PaO2, the severe and non-severe type defining features, 376

according to the Diagnosis and Treatment Plan (9), were also excluded. randomly dropped 5% data to simulate potential data loss, re-extrapolated the data with PMM, 387

and evaluated the mean square root error (RMSE) between the original and imputed datasets. 388

The RMSE was less than 0.05, indicating the extrapolation was feasible and reliable. The 389

imputed data were then passed on to successive data mining and machine learning steps. 390

For the 0-1 binary features in symptom modality, we calculated the prevalence of each 391 feature, i.e., number of positives over the number of patients in each type, non-severe and severe. 392

Z-test was then applied to investigate whether there was a statistically significant difference of 393 prevalence of any binary feature between the two types. In addition, a forest plot of odds ratio 394 (OR) and its 95% confidence interval (CI) of symptom features between severe and non-severe 395 COVID-19 types was developed. 396

For the continuous features in biochemistry modality, we characterized and contrasted the 397 distribution of each feature in both types. Because most features were not normally distributed, 398

we applied a two-sided Kolmogorovs-Smirnov test instead of Student's t-test for each feature and 399 investigated whether these features distributed differently between the two types. Additionally, 400

principal component analysis (PCA) was applied to help visualize the distinction in feature 401 distributions and associations between the two clinical types. 402

Traditional hypothesis-driven parametric models, such as logistic regression, relied 404 heavily on human decisions of how features interact with each other (i.e., interaction terms in 405 logistic regression model), which might not reflect the underlying medical reality. In addition, 406 these models had strict prerequisites to perform correctly, for instance, normality of residuals, 407 homoscedasticity, and independence of input features. Initial exploratory analyses showed that 408 input features in both symptom and biochemistry modalities were non-normality and high 409 collinearity among the features. Another technical challenge to logistic regression in this study 410 was a mixture of binary symptom and continuous biochemistry variables from two modalities. 411

Bearing these problems, logistic regression would not be a preferable modeling approach 412

to accurately classify and predict COVID-19 clinical types. Our exploratory analysis showed that 413 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2020. . logistic regression could only achieve 68% and 77% predictive accuracy on an 80-20 training-414 prediction split, using symptom and biochemistry features, respectively (supplementary Table  415 S3). Thus, hypothesis-driven models such as logistic regression were less feasible in clinical 416 settings requiring high accuracy, sensitivity, and specificity to differentiate COVID-19 types. 417

On the other hand, state-of-the-art machine learning (ML) classification models worked 418 directly with the data to avoid human bias. In addition, ML models did not have restrictions on 419 how input data should be distributed or related. Therefore, ML classification would be a more 420 appropriate modeling approach to predict COVID-19 clinical type with complicated data 421 structure in this study. Therefore, we developed an end-to-end ML framework to accurately 422 predict COVID-19 patient's clinical type based on symptom and/or biochemistry modality 423 features. We built random forest (RF) classification models, as RF was able to provide excellent 424 interpretability of input variable's relative importance to support clinical decision-making. RF 425 was a widely used ML model based on decision theory and decision tree approach. The internal 426 validation process through bagging made RF especially accurate and reliable. RF was also robust 427 against data loss and data unbalancing, e.g., more non-severe type patients than severe patients in 428

our study (37-41). There were other types of ML classification methods though, for example, k-429 nearest neighbor, artificial neural network, and naive Beyes. However, the major goal of this 430 study was not to compare performances of different ML models, we focused on RF to deliver the 431 most accurate classification possible. 432 We assigned severe cases as "positive" and non-severe as "negative" in the classification. 433

The goal of ML classification through RF was to accurately predict the patient's COVID-19 type, 434 either "positive" (severe) or "negative" (non-severe), based on features from different clinical 435 modalities. In this part of study, we first use a single modality of features as input. In addition, we explored whether and how combining features across modalities 450 improved classification performance. In non-ML methods, it would be difficult to combine 0-1 451 binary inputs with continuous inputs. However, this challenge was non-existent in ML models 452 because ML models worked directly with data without a priori assumptions of the data structure. 453 We developed another RF model that incorporated features from both modalities. The 454 modeling process was exactly the same as using single modality. Nevertheless, instead of putting 455 every feature into the model, we selected top 5 features from each of the two modalities as new 456

inputs. These top features were identified from the Gini impurity of single modality RF models 457 (supplementary Table S1 and S2). We explored whether a few important features from different 458 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Competing interests: the authors declare no competing interests in this study. 593 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2020. . Data and materials availability: de-identified clinical data and codes in this study sare openly 594 available on GitHub (https://github.com/forrestbao/corona/tree/master/blood) 595 596

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105841 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105841 doi: medRxiv preprint severe types from machine learning random forest (RF) model. 660 661 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105841 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105841 doi: medRxiv preprint

A general report on the systematic anatomy of COVID-19

High Prevalence of Concurrent Gastrointestinal Manifestations in Patients 507 with SARS-CoV-2: Early Experience from California

Potential 510 influence of COVID-19/ACE2 on the female reproductive system

A first case of 513 meningitis/encephalitis associated with SARS-Coronavirus-2

An interpretable mortality prediction model for 516 COVID-19 patients

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the 518 peripheral blood of SARS-CoV-2 infected patients

Development 521 and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in 522 Hospitalized Patients With COVID-19

ACE and ACE2 in kidney disease

ACE2 administration slows kidney damage

Clinical course and outcomes of critically ill 530 patients with SARS CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, 531 observational study

Retrospective analysis of laboratory testing in 54 patients with 533 severe-or critical-type 2019 novel coronavirus pneumonia

The ACE2 expression in human heart indicates 536 new potential mechanism of heart injury among patients

Association of Cardiac Injury With Mortality in Hospitalized 539 Patients With COVID-19 in Wuhan, China

The impact of 2019 novel coronavirus on heart 542 injury: A Systematic review and Meta-analysis

Risk factors associated with acute respiratory distress 545 syndrome and death in patients with coronavirus disease 2019 pneumonia inWuhan, China. 546

Clinical characteristics of coronavirus disease 2019 in China

Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease

Targeting potential drivers of COVID-554 19: Neutrophil extracellular traps

Comorbidities and multi-organ 558 injuries in the treatment of COVID-19

How does coronavirus kill? Clinicians 561 trace a ferocious rampage through the body, from brain to toes

Hospitalization Rates and Characteristics of Patients 564 Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 565 States

DOI

Introduction to decision tree

Random decision forests

From local explanations to global understanding with explainable AI for 571 trees

Classification with correlated features: unreliability of feature 573 ranking and solutions

Unbiased split selection for classification trees based 575 on the Gini index

Clinical course and risk factors for 577 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

non-severe and severe COVID-19 patients. 460 All statistical analyses and ML models were built in R 3.5.0. and Python 3.7 with 461 additional supporting packages. The codes and fully de-identified data would be freely available 462on GitHub (https://github.com/forrestbao/corona/tree/master/blood